Administer Leqemi 10 mg/kg, every two weeks. for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 Feb 2024: Trial started, NCT07034222
  2. 24 Jun 2025: Trial registered, NCT07034222

The trials

NCT07034222: 12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease

State
Under way
Phase
Phase 4
People
80 planned
Started
1 Feb 2024
Primary completion
1 Jan 2026
Arms
Lecanemab treatment group
Results
None posted
  1. 1 Feb 2024: Trial started
  2. 24 Jun 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.